“It has been known for some time that some diabetes drugs, including repaglinide, may have anti-inflammatory properties in nondiabetic animals, but doses required for clinical efficacy belie a practical application. Before considering a clinical trial of diabetes management in patients presenting with the polymyalgic syndrome, which may risk harm from poorly managed disease, a more definitive epidemiologic study should be considered. In my opinion, there isn’t evidence of an important pathogenetic link between PMR and diabetes,” he says.
Reference
ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
- Yoshida K, Sakamoto N, Kurosaka D. Improvement in polymyalgia rheumatica associated with improved control of diabetes mellitus: A case series. Ann Intern Med. 2020 Sep 15. doi: 10.7326/L20-0196. Online ahead of print.